학술논문
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
Document Type
article
Author
Glenn A. Marsh; Alexander J. McAuley; Gough G. Au; Sarah Riddell; Daniel Layton; Nagendrakumar B. Singanallur; Rachel Layton; Jean Payne; Peter A. Durr; Hannah Bender; Jennifer A. Barr; John Bingham; Victoria Boyd; Sheree Brown; Matthew P. Bruce; Kathie Burkett; Teresa Eastwood; Sarah Edwards; Tamara Gough; Kim Halpin; Jenni Harper; Clare Holmes; William S. J. Horman; Petrus Jansen van Vuren; Suzanne Lowther; Kate Maynard; Kristen D. McAuley; Matthew J. Neave; Timothy Poole; Christina Rootes; Brenton Rowe; Elisha Soldani; Vittoria Stevens; Cameron R. Stewart; Willy W. Suen; Mary Tachedjian; Shawn Todd; Lee Trinidad; Duane Walter; Naomi Watson; Trevor W. Drew; Sarah C. Gilbert; Teresa Lambe; S. S. Vasan
Source
npj Vaccines, Vol 6, Iss 1, Pp 1-8 (2021)
Subject
Language
English
ISSN
2059-0105
Abstract
Abstract Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via the intramuscular or intranasal route. All ChAdOx1 nCoV-19 administration combinations resulted in significant reductions in viral loads in nasal-wash and oral swab samples. No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate.